Protein / target

Dihydropteroate synthase

folP1P0C0X1Mycobacterium leprae (strain TN)Swiss-Prot
UniProt: P0C0X1
23
Clinical trials
1
Drugs targeting

Protein at a glance

Biological role

Dihydropteroate synthase activity

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function

Catalyzes the condensation of para-aminobenzoate (pABA) with 6-hydroxymethyl-7,8-dihydropterin diphosphate (DHPt-PP) to form 7,8-dihydropteroate, the immediate precursor of folate derivatives

Domains and Gene Ontology detail (6)

Domains & features

Pterin-binding

Gene Ontology

  • Ccytosol
  • Fdihydropteroate synthase activity
  • Fmetal ion binding
  • Pfolic acid biosynthetic process
  • Ptetrahydrofolate biosynthetic process

284 aa · 29 kDa

Drugs targeting this protein

1

Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.

Dapsone
Narrow target profileInhibitor

Dihydropteroate synthase 1 inhibitor

Direct interaction with this protein · Only this protein recorded as a target

ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.

Clinical trials

23

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.

Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients and Its Relation to Multiple Drug Therapy: Randomized Clinical TrialNA

RECRUITING · via Dapsone · NCT06819449

A Single-center, Double-blind, Randomized, Parallel-group Study, Comparing DPSG to a Placebo Control in the Treatment of Acne VulgarisPHASE1

COMPLETED · via Dapsone · NCT03132194

Neuroprotective Effect of Dapsone in Patients With Aneurysmal Subarachnoid Hemorrhage: Prospective, Randomized, Double-Blinded, Placebo-Controlled, Clinical TrialPHASE3

COMPLETED · via Dapsone · NCT05131295

Prospective Multicenter Randomized Open-label Controlled Trial Assessing Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune ThrombocytopeniaPHASE3

UNKNOWN · via Dapsone · NCT02627417

Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole and Dapsone and Their Hydroxylamine MetabolitesPHASE1

COMPLETED · via Dapsone · NCT00000826

A Randomized Multicenter Study for Isolated Skin VasculitisPHASE2

RECRUITING · via Dapsone · NCT02939573

Show remaining trials (17)
Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV InfectionPHASE1

COMPLETED · via Dapsone · NCT00000739

A Randomized Trial of Three Anti-Pneumocystis Agents Plus Zidovudine for the Primary Prevention of Serious Infections in Patients With Advanced HIV InfectionPHASE3

COMPLETED · via Dapsone · NCT00000991

A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or SulfonamidesPHASE3

COMPLETED · via Dapsone · NCT00000802

A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity SyndromePHASE4

UNKNOWN · via Dapsone · NCT02550080

Population Pharmacokinetic Analysis of Dapsone in Normal, Overweight and Obese VolunteersPHASE4

COMPLETED · via Dapsone · NCT01165840

Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis Carinii PneumoniaPHASE1

COMPLETED · via Dapsone · NCT00002120

A Prospective Randomized Placebo-Controlled Clinical Trial of Dapsone as a Glucocorticoid-Sparing Agent in Maintenance Phase Pemphigus VulgarisPHASE2

TERMINATED · via Dapsone · NCT00429533

Off Label Use of Dapsone in SARS-CoV-2 Hospitalized PatientsEARLY_PHASE1

UNKNOWN · via Dapsone · NCT04918914

Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne VulgarisPHASE4

COMPLETED · via Dapsone · NCT00834210

Diffuse Fibrotic Lung DiseasePHASE2

COMPLETED · via Dapsone · NCT00000596

Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)NA

COMPLETED · via Dapsone · NCT00002043

A Phase III Comparative Study of Dapsone / Trimethoprim and Clindamycin / Primaquine Versus Trimethoprim / Sulfamethoxazole in the Treatment of Mild-to-Moderate PCP in Patients With AIDSPHASE3

COMPLETED · via Dapsone · NCT00000640

Clinical Trial Randomized, Placebo-controlled, Using Dapsone as a Neuroprotector During Acute Ischemia StrokePHASE2/PHASE3

UNKNOWN · via Dapsone · NCT01144650

Efficacy and Safety of add-on Dapsone Versus add-on Methotrexate in Patients With Bullous Pemphigoid: A Randomized Controlled TrialPHASE4

COMPLETED · via Dapsone · NCT05984381

A Randomized, Comparative, Prospective Study of Monthly Aerosolized Pentamidine and Thrice Weekly Dapsone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant to Trimethoprim and/or SulfonamidesPHASE3

COMPLETED · via Dapsone · NCT00001028

Phenotypic and Genotypic Evaluation of Cytochrome P450 Isoforms in Populations of Different Ethnic CompositionNA

UNKNOWN · via Dapsone · NCT00162383

Randomized Prospective Study of Dapsone Versus Trimethoprim-Sulfamethoxazole in the Treatment of First Episode Pneumocystis Carinii Pneumonia in AIDS PatientsNA

COMPLETED · via Dapsone · NCT00002283

ClinicalTrials.gov via the drug-target graph.

What's happening now

4

Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.

  1. Regulatory approval2026-07-08

    Approval: DAPSONE (ANDA218335)

    fda · regulatory · fda · via Dapsone

  2. Regulatory approval2026-06-25

    Approval: DAPSONE (ANDA213414)

    fda · regulatory · fda · via Dapsone

  3. Product recall2024-10-29

    Recall (Class II): DAPSONE

    fda · safety · fda · via Dapsone

  4. New publication2019-06-11
    Dermatitis Herpetiformis: Novel Perspectives.

    Frontiers in immunology · 2019 · 51 citations · Europe PMC · via Dapsone

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.